Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 7/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.72 |
| ▸ | TNF | P01375 | 4/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21247383 | 0.87 | MAPT (0.73) | MAPTMEN1KMT2ATNFNOD1 | |
| SCHEMBL918283 | 0.86 | MAPT (1.00) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL21247135 | 0.84 | MEN1 (1.00) | MAPTMEN1KMT2ATNFNOD1 | |
| SCHEMBL21247391 | 0.84 | MEN1 (0.95) | MAPTMEN1KMT2ATNFNOD1 | |
| SCHEMBL8288554 | 0.81 | NPC1 (0.72) | MAPTMEN1KMT2ATNFNOD1 | |
| SCHEMBL22696749 | 0.81 | MEN1 (0.57) | MAPTMEN1KMT2ATNFNOD1 | |
| SCHEMBL3921416 | 0.80 | MEN1 (1.00) | MAPTMEN1KMT2ATNFNOD1 | |
| SCHEMBL7901259 | 0.78 | TP53 (0.81) | MAPTMEN1KMT2ATNFNOD1 | |
| SCHEMBL2182372 | 0.78 | TP53 (0.80) | MAPTMEN1KMT2ATNFNOD1 | |
| SCHEMBL21260633 | 0.76 | TNF (0.62) | MAPTMEN1KMT2ATNFNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749658-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | claimed |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | claimed |
| WO-2019154949-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | claimed |
| US-11603368-B2 | Fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-03-14 | — | — | US | disclosed |
| EP-3749658-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| WO-2019154949-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019154949-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | MAPT 2107/4885MEN1 3538/4885KMT2A 3454/4885 |
| US-11603368-B2 | Fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | MAPT 2107/4885MEN1 3538/4885KMT2A 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.